Pimozide and Imipramine Blue Exploit Mitochondrial Vulnerabilities and Reactive Oxygen Species to Cooperatively Target High Risk Acute Myeloid Leukemia

• Autores principales: Zhengqi Wang (Autor), Tian Mi (Autor), Heath L. Bradley (Autor), Jonathan Metts (Autor), Himalee Sabnis (Autor), Wandi Zhu (Autor), Jack Arbiser (Autor), Kevin D. Bunting (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2021-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Acute myeloid leukemia (AML) is a heterogeneous disease with a high relapse rate. Cytokine receptor targeted therapies are therapeutically attractive but are subject to resistance-conferring mutations. Likewise, targeting downstream signaling pathways has been difficult. Recent success in the develo...